C4 Therapeutics (CCCC) AI Stock Analysis

698 Followers

C4 Therapeutics

(NASDAQ:CCCC)

Select Model

Rating:47Neutral

Price Target:$3.50▲(9.03% Upside)

Action:reiterated

Date:09/25/26

Overall score is held down primarily by weak financial performance—ongoing heavy losses and material cash burn alongside declining TTM revenue. Technicals also lean bearish with the stock trading below major moving averages, partially offset by oversold indicators. A positive clinical data update provides some support, but valuation remains hard to anchor given negative earnings and no dividend.

Positive Factors

Targeted protein degradation platformC4 Therapeutics applies a differentiated targeted protein degradation platform to cancer biology, including proteins that may resist traditional inhibition. This creates a potentially durable scientific edge if the approach continues producing viable candidates and supports a broader oncology pipeline over time.

Negative Factors

Declining revenue baseRevenue contraction is weakening an already small commercial and collaboration-related base, limiting the company’s ability to offset research and development spending. Unless pipeline progress produces stronger revenue support, declining top-line performance can prolong reliance on external financing.

C4 Therapeutics (CCCC) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $394.91M
Dividend Yield: ―
Average Volume (3M): 2.42M
Price to Earnings (P/E): -3.2
Beta (1Y): 2.32
Revenue Growth: 2.33%
EPS Growth: 36.86%
Country: US
Employees: 104
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

C4 Therapeutics Business Overview & Revenue Model

Company Description

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions includi...

C4 Therapeutics Financial Statement Overview

Summary

Financial performance is weak: TTM revenue declined ~18.5%, operating losses remain substantial (net margin near -298%), and cash burn is significant (TTM operating cash flow about -$84.9M; free cash flow about -$85.4M). The main offset is a relatively manageable leverage profile (TTM debt-to-equity ~0.25) and meaningful equity base, but sharply negative returns (ROE around -51%) highlight ongoing funding/runway risk.

Income Statement

23Negative

Balance Sheet

54Neutral

Cash Flow

28Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	35.04M	35.95M	35.58M	20.76M	31.10M	45.78M
Gross Profit	33.24M	27.97M	35.58M	13.02M	31.10M	45.78M
EBITDA	-99.71M	-102.91M	-103.37M	-127.96M	-124.28M	-80.25M
Net Income	-101.42M	-104.99M	-105.32M	-132.49M	-128.18M	-83.89M
Balance Sheet
Total Assets	359.40M	359.07M	349.60M	376.45M	430.84M	506.76M
Cash, Cash Equivalents and Short-Term Investments	253.66M	248.54M	244.90M	253.68M	276.15M	309.28M
Total Debt	56.86M	59.98M	65.76M	70.98M	87.15M	42.88M
Total Liabilities	112.14M	102.49M	133.62M	130.34M	141.61M	117.16M
Stockholders Equity	247.26M	256.59M	215.99M	246.11M	289.23M	389.61M
Cash Flow
Free Cash Flow	-85.39M	-99.30M	-65.34M	-108.55M	-111.44M	-88.24M
Operating Cash Flow	-84.87M	-98.69M	-65.16M	-106.84M	-105.94M	-86.97M
Investing Cash Flow	-75.31M	-8.60M	-51.27M	158.35M	58.42M	-189.34M
Financing Cash Flow	160.63M	126.40M	45.34M	45.49M	1.15M	171.40M

C4 Therapeutics Technical Analysis

Technical Analysis SentimentNeutral

Last Price3.21

Price Trends

50DMA3.29Negative

100DMA3.61Negative

200DMA3.22Negative

Market Momentum

MACD0.02Negative

RSI51.61Neutral

STOCH55.94Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Neutral. The current price of 3.21 is above the 20-day moving average (MA) of 3.05, below the 50-day MA of 3.29, and below the 200-day MA of 3.22, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 51.61 is Neutral, neither overbought nor oversold. The STOCH value of 55.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CCCC.

C4 Therapeutics Risk Analysis

C4 Therapeutics disclosed 73 risk factors in its most recent earnings report. C4 Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

C4 Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CCCC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TVGN	48Neutral	$36.40M	-1.01	248.50%	―	―	36.06%
CCCC	47Neutral	$394.91M	-3.21	-45.45%	―	2.33%	36.86%
ELDN	46Neutral	$212.90M	-2.65	-136.45%	―	―	-1475.42%
SLS	45Neutral	$1.73B	-41.98	-35.91%	―	―	35.38%
MCRB	41Neutral	$18.19M	-0.82	-60.32%	―	―	71.26%

* Healthcare Sector Average

Performance Comparison

CCCC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CCCC	C4 Therapeutics, Inc.	3.21	0.84	35.44%
SLS	Sellas Life Sciences Group	8.87	7.19	427.98%
MCRB	Seres Therapeutics Inc.	1.96	-10.74	-84.57%
ELDN	Eledon Pharmaceuticals, Inc.	2.62	-1.41	-34.99%
TVGN	Tevogen Bio Holdings Inc.	5.92	-20.33	-77.45%
ACTU	Actuate Therapeutics, Inc.	0.35	-6.11	-94.58%

C4 Therapeutics Corporate Events

Business Operations and StrategyProduct-Related Announcements

C4 Therapeutics Reports New Cemsidomide Myeloma Data

Positive

Sep 25, 2026

On September 25, 2026, C4 Therapeutics presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and Phase 1b trial with elranatamab in relapsed or refractory multiple myeloma at the International Myeloma Society annual me...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 25, 2026

C4 Therapeutics AI Stock Analysis